• editor.aipublications@gmail.com
  • Track Your Paper
  • Contact Us
  • ISSN: 2456-8015

International Journal Of Medical, Pharmacy And Drug Research(IJMPD)

Understanding Therapeutic drug monitoring (TDM) at a glance

Abdullah Al Noman , Anupama Chakraborty , Honufa Akter , , Raisa Mustafa Binti

International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-7,Issue-1, January - February 2023, Pages 1-6 , 10.22161/ijmpd.7.1.1

Download | Downloads : 2 | Total View : 129

Article Info: Received: 11 Dec 2022; Received in revised form: 13 Jan 2023; Accepted: 01 Feb 2023; Available online: 28 Feb 2023


This paper gives an overview of therapeutic drug monitoring. The primary objectives of TDM are to prevent therapeutic failures carried on by poor compliance or prescribing a drug at a dose that is too low, as well as negative or toxic effects brought on by an excessive dose. Moreover, it gives information about when and what type of drug needs therapeutic drug monitoring. Like the drug which has a short therapeutic window they require therapeutic monitoring because it can cause toxicity or no therapeutic effect. However, the appropriate use of TDM is not only the simple measurement of patient blood drug concentration and the comparison of its target range but also TDM plays an important role in the therapeutic medication by ensuring safety and effectiveness also with individualization of these medications, desired clinical targets, dosage history, sampling time in relation to the dose patient’s response these factors needed to be considered while interpreting drug concentration measurements to achieve the optimal response with minimal toxicity. So TDM can be considered as a combined approach encompassing pharmaceutical, pharmacokinetic, pharmacodynamic techniques and analyses.

Therapeutic drug monitoring, therapeutic window, less efficiency, toxicity, blood serum level.

[1] Kang JS, Lee MH. Overview of Therapeutic Drug Monitoring. Korean J Intern Med [Internet]. 2009 [cited 2023 Jan 16];24(1):1. Available from: /pmc/articles/PMC2687654/
[2] Bowers LD. Analytical goals in therapeutic drug monitoring [Internet]. Available from: https://academic.oup.com/clinchem/article/44/2/375/5642505
[3] Rane CT, Dalvi SS, Gogtay NJ, Shah PU, Kshirsagar NA. A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001;52(2):193–5.
[4] Soldin OP, Soldin SJ. Review: Therapeutic Drug Monitoring in Pediatrics. 2002.
[5] Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-Effectiveness of Therapeutic Drug Monitoring A Systematic Review [Internet]. Available from: http://ctfphc.org/methods.htm.
[6] Tamargo J, le Heuzey JY, Mabo P. Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.
[7] Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, et al. Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015) ― Digest Version ―. Circulation Journal. 2017;81(4):581–612.
[8] Andrews LM, Riva N, de Winter BC, Hesselink DA, de Wildt SN, Cransberg K, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Vol. 11, Expert Opinion on Drug Metabolism and Toxicology. Informa Healthcare; 2015. p. 921–36.
[9] Aminoglycosides: Recommendations for use, dosing and monitoring Clinical Guideline.
[10] Tomson T, Dahl ML, Kimland E. Therapeutic monitoring of antiepileptic drugs for epilepsy. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2007.
[11] Jannuzzi G, Cian P, Fattore C, Gatti G, Bartoli A, Monaco F, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia. 2000;41(2):222–30.
[12] Cooney L, Loke YK, Golder S, Kirkham J, Jorgensen A, Sinha I, et al. Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice. BMC Med Res Methodol. 2017 Dec 2;17(1):84.
[13] Mould D, Upton R. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods. CPT Pharmacometrics Syst Pharmacol. 2013 Apr;2(4):38.
[14] Wadhwa RR, Cascella M. Steady State Concentration. StatPearls [Internet]. 2022 Mar 9 [cited 2023 Jan 16]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK553132/
[15] Ates HC, Roberts JA, Lipman J, Cass AEG, Urban GA, Dincer C. On-Site Therapeutic Drug Monitoring. Trends Biotechnol [Internet]. 2020 Nov 1 [cited 2023 Jan 17];38(11):1262–77. Available from: http://www.cell.com/article/S0167779920300615/fulltext
[16] Kidd JM, Asempa TE, Abdelraouf K. Therapeutic drug monitoring. Remington: The Science and Practice of Pharmacy. 2021 Jan 1;243–62.